RapidAI celebrates one-millionth scan leveraging big-data to fuel AI and the future of stroke imaging
July 28, 2020
MENLO PARK, Calif.--(BUSINESS WIRE)--RapidAI, the worldwide leader in advanced imaging for stroke, today announced that Thomas Jefferson University Hospital in Philadelphia was the site of the one-millionth recorded Rapid® scan. Building on its leadership in AI-powered stroke imaging, with this news RapidAI fortifies its standing as the most widely used, clinically validated stroke imaging software for patient care, research, and clinical trials.
Based on intelligence gained from an unmatched 1,000,000+ scans from more than 1,600 hospitals in over 50 countries, the artificial intelligence-based Rapid platform creates high-quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans. The platform offers an end-to-end portfolio of advanced cerebrovascular imaging analysis products—including Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid CTP, and Rapid MRI.
Now, with over one million scans, RapidAI can leverage even more statistical power and data to enhance performance and improve patient care at individual hospitals as well as larger networks and systems around the world.
With its region-wide reputation for quality stroke care, Thomas Jefferson University Hospital in Philadelphia, Pennsylvania, has been awarded the distinction of the one-millionth recorded Rapid scan.
“Stroke imaging and care have evolved quickly over the last couple of years, thanks in large part to innovations from the likes of RapidAI as well as expanded AHA/ASA stroke guidelines,” said Pascal Jabbour, MD, Professor of Neurological Surgery and the Chief of the Division of Neurovascular and Endovascular Neurosurgery in the Department of Neurological Surgery at the Sidney Kimmel Medical College at Thomas Jefferson University. “We are gratified to be the site of the one-millionth Rapid scan as we are always in pursuit of the tools, techniques and intelligence that lead to better patient outcomes.”
The complete Rapid platform currently includes:
Rapid ICH: automatically triages non-contrast CT scans to quickly identify brain hemorrhages
Rapid ASPECTS: automatically identifies areas of early ischemic change on non-contrast CT scans, which predicts irreversible injury
Rapid CTA: automatically assesses regions of reduced blood flow to identify, locate, and alert stroke teams to the presence of large vessel occlusions (LVOs)
Rapid CTP: fully-automated perfusion maps; accurately quantifies reduced cerebral blood flow, cerebral blood volume and transit time
Rapid MRI: fully-automated diffusion and perfusion maps that quantify brain areas with low ADC values, as well as delayed contrast arrival
Rapid Mobile App: securely preview RapidAI results from multiple sites, receive notifications, and communicate about patient care, anytime, anywhere
“It is with great excitement that we honor Thomas Jefferson University Hospital for the one millionth recorded Rapid scan. In parallel, this builds on the over 1,600 hospitals in the U.S. and around the world that rely on RapidAI technology as an integral part of their stroke care every day,” said Don Listwin, CEO of RapidAI. “Also, with the aggregate data of over one million scans, along with predictive algorithms and our Rapid Insights analytics solution, we can help benchmark data, performance and clinical workflow for single hospital sites and whole networks, improving everyone’s stroke IQ.”
RapidAI is the worldwide leader in advanced imaging for stroke. Installed in over 1,600 hospitals in more than 50 countries, the Rapid imaging platform, powered by artificial intelligence, includes Rapid CTP, Rapid MRI, Rapid CTA, Rapid ICH, and Rapid ASPECTS. RapidAI empowers clinicians to make faster, more accurate diagnostic and treatment decisions for stroke patients using clinically proven, data-driven technology. With our validated, trusted platform, developed by stroke experts, clinicians worldwide are improving patient care and outcomes every day. The Rapid platform has been shown to aid in patient selection in both early and late-window clinical stroke trials. In addition to achieving the best clinical outcomes and largest treatment effects ever obtained, the results of these trials led to new American Heart Association and American Stroke Association treatment guidelines and have dramatically altered the management of acute stroke around the world.